Display options
Cite
Chen JH, Chen WL, Chan JY, et al. Overexpression of CD164 in oral cavity squamous cell carcinoma predicts a favourable prognosis. Oncol Lett. 2017;14(5):6103-6108doi: 10.3892/ol.2017.6966.
Chen, J. H., Chen, W. L., Chan, J. Y., Chen, Y. W., Peng, Y. J., Cheng, M. F., & Lin, C. S. (2017). Overexpression of CD164 in oral cavity squamous cell carcinoma predicts a favourable prognosis. Oncology letters, 14(5), 6103-6108. https://doi.org/10.3892/ol.2017.6966
Chen, Jia-Hong, et al. "Overexpression of CD164 in oral cavity squamous cell carcinoma predicts a favourable prognosis." Oncology letters vol. 14,5 (2017): 6103-6108. doi: https://doi.org/10.3892/ol.2017.6966
Chen JH, Chen WL, Chan JY, Chen YW, Peng YJ, Cheng MF, Lin CS. Overexpression of CD164 in oral cavity squamous cell carcinoma predicts a favourable prognosis. Oncol Lett. 2017 Nov;14(5):6103-6108. doi: 10.3892/ol.2017.6966. Epub 2017 Sep 15. PMID: 29113253; PMCID: PMC5661421.
Copy Download .nbib Format: NLM
Share it on

Oncol Lett. 2017 Nov;14(5):6103-6108. doi: 10.3892/ol.2017.6966. Epub 2017 Sep 15.

Overexpression of CD164 in oral cavity squamous cell carcinoma predicts a favourable prognosis.

Oncology letters

Jia-Hong Chen, Wei-Liang Chen, James Yi-Hsin Chan, Yuan-Wu Chen, Yi-Jen Peng, Ming-Fang Cheng, Chun-Shu Lin

Affiliations

  1. Division of Medical Oncology and Haematology, Tri-Service General Hospital, National Defense Medical Centre, Taipei 11490, Taiwan, R.O.C.
  2. Division of Family Medicine, Tri-Service General Hospital, National Defense Medical Centre, Taipei 11490, Taiwan, R.O.C.
  3. Graduate Institute of Medical Sciences, Tri-Service General Hospital, National Defense Medical Centre, Taipei 11490, Taiwan, R.O.C.
  4. Department of Oral and Maxillofacial Surgery, Tri-Service General Hospital, National Defense Medical Centre, Taipei 11490, Taiwan, R.O.C.
  5. Department of Pathology, Tri-Service General Hospital, National Defense Medical Centre, Taipei 11490, Taiwan, R.O.C.
  6. Division of Histological and Clinical Pathology, Hualien Armed Forces General Hospital, Hualien 97144, Taiwan, R.O.C.
  7. Department of Radiation Oncology, Tri-Service General Hospital, National Defense Medical Centre, Taipei 11490, Taiwan, R.O.C.

PMID: 29113253 PMCID: PMC5661421 DOI: 10.3892/ol.2017.6966

Abstract

The aim of the present study was to investigate the association between cluster of differentiation (CD) 164 expression with clinicopathological parameters and prognosis among patients with oral cavity squamous cell carcinoma (OSCC). The present study retrospectively reviewed 70 patients with OSCC who underwent curative primary surgery. A number of patients subsequently received postoperative chemoradiotherapy although the specimens were not exposed to radiation or chemotherapy prior to anti-CD164 antibody immunohistochemical staining. CD164 overexpression was arbitrarily defined as exhibiting an H-score of ≥120. Univariate and multivariate analyses were performed for sex, age, American Joint Committee on Cancer stage, tumour location, histological grade, surgical margin and H-score. The 5-year overall survival rate was 54.4% and the median follow-up time was 46 months for surviving patients. Univariate analyses revealed that a low overall survival rate was associated with advanced-stage disease (P<0.001), buccogingival tumour location (P=0.038) and a CD164 H-score of <120 (P=0.016). Multivariate Cox's regression analyses revealed that poor overall survival rate was associated with advanced-stage disease (P=0.001) and a CD164 H-score of <120 (P=0.04). CD164 overexpression in OSCC was associated with favourable survival rate. Thus, CD164 expression may be a clinically useful predictor of prognosis in patients with OSCC.

Keywords: cluster of differentiation 164; endolyn; oral cavity cancer; oral cavity squamous cell carcinoma; survival

References

  1. Head Neck. 2006 Feb;28(2):150-7 - PubMed
  2. Blood. 1998 Aug 1;92(3):849-66 - PubMed
  3. Eur J Biochem. 1999 Oct 1;265(1):466-72 - PubMed
  4. Cancer. 1990 Nov 1;66(9):1861-8 - PubMed
  5. Lung Cancer. 2013 Nov;82(2):231-7 - PubMed
  6. J Clin Oncol. 1999 Mar;17(3):1008-19 - PubMed
  7. Blood. 1998 Oct 15;92(8):2613-28 - PubMed
  8. BMC Cancer. 2006 Jul 21;6:195 - PubMed
  9. Head Neck. 2013 Jan;35(1):65-71 - PubMed
  10. Clin Cancer Res. 2008 Jan 15;14(2):366-9 - PubMed
  11. Blood. 2000 May 15;95(10):3113-24 - PubMed
  12. Int J Mol Med. 2014 Jul;34(1):237-43 - PubMed
  13. Tissue Antigens. 2005 Mar;65(3):220-39 - PubMed
  14. Acta Derm Venereol. 2016 May;96(4):464-7 - PubMed
  15. Cancer Lett. 2015 Nov 1;368(1):36-45 - PubMed
  16. N Engl J Med. 2004 May 6;350(19):1937-44 - PubMed
  17. J Invest Dermatol. 2014 Jan;134(1):229-236 - PubMed
  18. Ann Surg Oncol. 2010 Jun;17(6):1471-4 - PubMed
  19. Radiother Oncol. 2011 Jul;100(1):33-40 - PubMed
  20. Int J Cancer. 2010 Dec 15;127(12):2893-917 - PubMed
  21. Dis Mon. 2001 Jul;47(7):275-361 - PubMed
  22. J Clin Oncol. 2008 Jul 20;26(21):3582-9 - PubMed
  23. Eur J Cancer. 2002 Feb;38(3):387-91 - PubMed
  24. Stem Cells. 2003;21(2):162-70 - PubMed
  25. Cancer Invest. 2012 Jun;30(5):380-9 - PubMed
  26. J Biochem. 2000 Jun;127(6):1103-7 - PubMed
  27. Int J Radiat Oncol Biol Phys. 2015 Dec 1;93(5):976-85 - PubMed
  28. Mol Cancer. 2013 Oct 05;12(1):115 - PubMed
  29. J Immunol. 2000 Jul 15;165(2):840-51 - PubMed

Publication Types